HighTower Advisors LLC Decreases Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

HighTower Advisors LLC lowered its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 6.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,585 shares of the company’s stock after selling 1,126 shares during the period. HighTower Advisors LLC’s holdings in Fresenius Medical Care were worth $349,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Allworth Financial LP boosted its holdings in shares of Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after purchasing an additional 581 shares during the period. GAMMA Investing LLC raised its position in Fresenius Medical Care by 50.4% during the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after purchasing an additional 1,675 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in Fresenius Medical Care in the 3rd quarter worth approximately $112,000. Venturi Wealth Management LLC grew its position in shares of Fresenius Medical Care by 1,045.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after buying an additional 4,800 shares during the last quarter. Finally, Signaturefd LLC increased its stake in shares of Fresenius Medical Care by 8.4% during the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after buying an additional 672 shares during the period. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Stock Performance

Shares of FMS stock opened at $22.81 on Monday. The company’s fifty day moving average price is $21.82 and its 200-day moving average price is $20.54. The stock has a market cap of $13.39 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 0.96 and a beta of 0.94. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. Fresenius Medical Care AG has a 12 month low of $17.93 and a 12 month high of $24.31.

Analyst Upgrades and Downgrades

A number of analysts recently commented on FMS shares. StockNews.com assumed coverage on Fresenius Medical Care in a research note on Thursday, November 28th. They issued a “strong-buy” rating for the company. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company. Truist Financial boosted their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Fresenius Medical Care currently has an average rating of “Hold” and an average price target of $24.30.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.